No Data
Chongqing Taiji Industry (600129.SH): Exploring the efficacy of pharmaceuticals and analyzing the mechanism of action of traditional Chinese medicine with multiple targets, components, and pathways through a large AI model of traditional Chinese medicine.
Gelonghui November 22nd | Chongqing Taiji Industry (600129.SH) stated on the investor interaction platform that the company explores the efficacy of pharmaceuticals and analyzes the mechanism of action of traditional Chinese medicine with multiple targets, components, and pathways through traditional Chinese medicine AI large models.
Chongqing taiji industry (600129.SH): has not engaged in real estate and retirement-related businesses.
Gelonghui November 22nd, chongqing taiji industry (600129.SH) stated on the investor interaction platform that the company does not engage in real estate, retirement, and other related businesses.
Zhongtai Securities: Traditional Chinese medicine companies are under pressure in the third quarter of 24Q3, with a slight rebound in end demand.
In Q3 2024, traditional Chinese medicine companies are facing temporary performance pressure, but the gross margin is expected to improve upwards starting in 2025.
Chongqing Taiji Industry (600129.SH): Sichuan Tiancheng Pharmaceutical has received a total of 75 million yuan in compensation for all demolition and relocation.
Chongqing Taiji Industry (600129.SH) announced on November 14th that sichuan Tiancheng Pharmaceutical has received a total of 75 million yuan in compensation for demolition as of the disclosure date of this announcement. The demolition compensation received this time will not have any impact on the company's profit in 2024.
Express News | chongqing taiji industry: currently, the mint cola flavor is already on sale online and in some offline areas.
China Great Wall Securities: Research and development of substitute products for rare traditional Chinese medicine ingredients receives support, expecting to accelerate the launch of new products.
On October 21, the National Medical Products Administration and the State Administration of Traditional Chinese Medicine jointly issued the "Notice on Supporting the Research and Development of Substitute Products for Rare and Endangered Traditional Chinese Medicines", proposing specific measures such as strengthening industry-university-research cooperation, enhancing technical guidance, and expediting reviews and approvals.
No Data
No Data